Atea Pharmaceuticals (NASDAQ:AVIR) Earns Outperform Rating from William Blair
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a research note issued to investors on Friday,RTT News reports. William Blair also issued estimates for Atea Pharmaceuticals’ Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) […]
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a research note issued to investors on Friday,RTT News reports. William Blair also issued estimates for Atea Pharmaceuticals’ Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) […]
